This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: E71.3 (Disorders of fatty-acid metabolism) | Special Copayment Reduction: V117 (ultra-rare disease, copayment exempt) |
| B. Synonyms | Muscle carnitine palmitoyltransferase deficiency, CPT1A deficiency, CPT2 deficiency, carnitine palmitoyltransferase deficiency, long-chain fatty acid oxidation disorder, CPT deficiency, carnitine transport defect |
| C. Adult onset | Possibility of first onset in adulthood: high — the myopathic form of CPT2 (myopathic CPT2) is the most common and typically first presents in adults in their 10s–30s with rhabdomyolysis and myalgia after exercise. CPT1A mainly presents in infancy, but patients with mild variants may also be first diagnosed in adulthood. |
| 1. History | 1973: first report of CPT deficiency by DiMauro·DiMauro → 1981: distinction between CPT1 and CPT2 established → 1992: CPT1A gene cloned → 1995: CPT2 gene cloned → discovery of the Inuit CPT1A variant (p.P479L). |
| 2. Causes | CPT1A (CPT1A gene, 11q13) deficiency: impaired hepatic long-chain FA transport. CPT2 (CPT2 gene, 1p32) deficiency: impaired reconversion of long-chain acylcarnitines within the mitochondrial matrix. Blockade of the carnitine transport cycle. |
| 3. Genetics | Autosomal recessive. CPT1A gene 11q13. CPT2 gene 1p32. High frequency of the Inuit CPT1A variant (p.Pro479Leu). Common CPT2 variant p.Ser113Leu (c.338C>T). |
| 4. General epidemiology | Myopathic CPT2: one of the most common muscle fatty acid oxidation disorders. High frequency of CPT1A among Inuit and Alaska Natives (1:50–1:100 births). Occurs in all ethnic groups worldwide. |
| 5. Pathophysiology | CPT1 converts long-chain FA to acylcarnitine (outer mitochondrial membrane), and CPT2 reconverts acylcarnitine to acyl-CoA within the mitochondrial matrix. Deficiency of either enzyme blocks mitochondrial beta-oxidation of long-chain FA. |
| 6. Symptoms | CPT1A: infantile hypoketotic hypoglycemia, hepatomegaly, liver dysfunction. Myopathic CPT2: myalgia, rhabdomyolysis and myoglobinuria after exercise. Neonatal CPT2: severe cardiomyopathy, liver failure, hypoglycemia. |
| 7. Signs | Elevated plasma C16 and C18 acylcarnitines (CPT2). In CPT1A, elevated free carnitine and low acylcarnitine ratio. Elevated CK (myopathic CPT2). Hypoketotic hypoglycemia (CPT1A). |
| 8. Screening | Newborn MS/MS acylcarnitine analysis. CPT2: elevated C16, C18. CPT1A: elevated C0 and low C16+C18 (low acyl/free carnitine ratio). Experience with screening in Inuit populations. |
| 9. Diagnosis | Plasma acylcarnitine analysis + urine organic acids + CPT1A or CPT2 gene analysis. Enzyme activity (fibroblasts). Exercise provocation test (myopathic CPT2). Muscle biopsy (CPT2 protein immunofluorescence). |
| 10. Treatment | CPT1A: avoidance of fasting, intravenous glucose in the acute phase, low-fat high-carbohydrate diet. Myopathic CPT2: carbohydrate intake before prolonged exercise, trial of riboflavin (B2). Medium-chain triglyceride (MCT) diet used in some cases. |
| 11. Prognosis | CPT1A: normal development possible with avoidance of fasting. Risk of death and brain damage if acute hypoglycemic crises are untreated. Myopathic CPT2: normal life possible with trigger avoidance. Neonatal multisystem CPT2: high mortality. |
| 12. Prevention | Newborn screening, genetic counseling, education on trigger avoidance (prolonged exercise, fasting, infection), preoperative consultation with metabolic specialists, carrying an emergency protocol card. |
| 13. References | DiMauro S, DiMauro PM. Science. 1973 (PMID 4125175) … and 9 other papers |
The history of carnitine palmitoyltransferase (CPT) deficiency begins with a landmark case report published by DiMauro and DiMauro in Science in 1973. They found markedly reduced CPT enzyme activity in two brothers who experienced recurrent myalgia and myoglobinuria after exercise, the first molecular characterization of exercise intolerance due to a fatty acid oxidation disorder. This report is regarded as a milestone discovery that clinically demonstrated the importance of fatty acids as an energy source for muscle.
CPT was initially recognized as a single enzyme, but from 1981 onward it was established that there are two independent enzymes: CPT1, located in the outer mitochondrial membrane, and CPT2, located in the inner mitochondrial membrane. CPT1 converts cytosolic long-chain fatty acyl-CoA to acylcarnitine, a form that can cross the inner mitochondrial membrane, and CPT2 reconverts acylcarnitine to acyl-CoA in the mitochondrial matrix so that it enters beta-oxidation. Deficiencies of the two enzymes cause different clinical phenotypes.
The CPT1A gene (liver form) was cloned in 1992 and the CPT2 gene in 1995, laying the foundation for molecular diagnosis. There are three isoforms of CPT1: CPT1A (mainly expressed in the liver), CPT1B (muscle and heart) and CPT1C (brain). Thus, CPT1A deficiency mainly causes a hepatic phenotype, and CPT1B deficiency causes muscle and cardiac phenotypes. Clinically, the best known are CPT1A deficiency (infantile hepatic phenotype) and CPT2 deficiency (myopathic form). In particular, a CPT1A variant (p.Pro479Leu) has been found at a very high frequency (1:50–1:100) in Alaska Native and Canadian Inuit populations, raising the possibility that this variant was historically an adaptive variant for fat metabolism in cold environments.
CPT deficiency is caused by deficiency of the enzymes that make up the carnitine shuttle, which is required for the transport of long-chain fatty acids into the mitochondria. Long-chain fatty acids (C14 and above) exist in the cell as acyl-CoA esters but cannot directly cross the inner mitochondrial membrane. To overcome this, CPT1 converts acyl-CoA to acylcarnitine, carnitine-acylcarnitine translocase (CACT) transports the acylcarnitine into the mitochondrial matrix, and CPT2 then reconverts it to acyl-CoA so that it enters beta-oxidation.
CPT1A deficiency: Pathogenic variants in the CPT1A gene (11q13.3) cause deficiency of the liver form of CPT1. Entry of long-chain fatty acids into hepatic mitochondria is blocked, so hepatic beta-oxidation is impossible during fasting and ketone body production is extremely limited. As a result, hypoketotic hypoglycemia and liver dysfunction develop. CPT1A is inhibited by malonyl-CoA, and abnormalities of this regulatory mechanism also contribute to the pathophysiology. The p.Pro479Leu variant, frequent in Inuit populations, reduces the enzyme's sensitivity to malonyl-CoA and thereby enhances fatty acid oxidation, which is sometimes interpreted as an adaptive variant that increases energy efficiency in cold environments.
CPT2 deficiency: Pathogenic variants in the CPT2 gene (1p32) cause deficiency of CPT2 in the inner mitochondrial membrane. Long-chain acylcarnitines cannot be reconverted to acyl-CoA in the mitochondrial matrix, blocking beta-oxidation. There are three main phenotypes. The myopathic form (adult form) is the most common; because some residual enzyme activity remains, symptoms appear only when the demand for long-chain FA oxidation is high, such as during exercise. The neonatal form is a severe form with almost complete enzyme deficiency in which cardiomyopathy, liver failure and hypoglycemia appear in the neonatal period. The infantile form is of intermediate severity, with hepatic symptoms during fever or fasting. The common variant p.Ser113Leu (c.338C>T) is associated with the myopathic form, while complete loss-of-function variants cause the neonatal form.
CPT deficiency follows an autosomal recessive mode of inheritance. The CPT1A gene is located on the long arm of chromosome 11 (11q13.3), is about 63 kb long and consists of 20 exons. The encoded CPT1A protein has 773 amino acids. The CPT2 gene is located on the short arm of chromosome 1 (1p32), is about 20 kb long and consists of 5 exons. The encoded CPT2 protein has 658 amino acids.
A notable CPT1A variant is p.Pro479Leu (c.1436C>T), which is very frequent in Alaska Native and Inuit populations; the carrier frequency in these populations is very high (1:3 in some regions), so many homozygous individuals exist. This variant retains residual enzyme activity, so clinical expression varies, and some individuals live without hypoglycemia. The muscle phenotype due to CPT1B deficiency arises from a separate gene (22q13.31), and this file mainly covers CPT1A and CPT2. The CPT2 variant most frequently associated with the myopathic form is p.Ser113Leu (c.338C>T); homozygosity or compound heterozygosity for it accounts for 60–70% of all myopathic CPT2 cases. Complete loss-of-function variants (nonsense, frameshift) are associated with the neonatal form.
Genetic testing is performed by NGS-based metabolic disease panels, WES or WGS. CPT1A p.Pro479Leu can also be rapidly confirmed by Sanger sequencing or targeted variant analysis. For compound heterozygous variants, parental testing is required to confirm phase. Prenatal diagnosis (CVS or amniocentesis) and PGT are possible when the familial variants have been identified.
CPT2 deficiency is one of the most common myopathic fatty acid oxidation disorders; its exact incidence is unknown but is estimated at about 1 in 40,000–100,000 births. Myopathic CPT2 tends to be diagnosed more often in males, which is understood to be because males engage in strenuous exercise more often and are therefore more likely to have symptoms triggered. There is no particular ethnic predilection, but frequency may be higher in certain regional populations due to founder variants.
The most notable epidemiological feature of CPT1A deficiency is its very high frequency in Alaska Native Americans and Canadian Inuit populations. The carrier frequency of the p.Pro479Leu variant reaches 1:2–1:3 in some populations, and the homozygote frequency is very high at 1:6–1:100. In these populations, CPT1A-related infant hypoglycemic deaths became a problem and screening programs were introduced. CPT1A deficiency is very rare in people of European and Asian ancestry. Epidemiological data from Korea are limited, but cases of CPT deficiency have been identified in the national rare disease registry, and it is eligible for Special Copayment Reduction V117.
The carnitine shuttle is the essential pathway by which long-chain fatty acids cross the inner mitochondrial membrane to enter beta-oxidation. This pathway consists of three key proteins: CPT1 (outer mitochondrial membrane), carnitine-acylcarnitine translocase (CACT, inner mitochondrial membrane) and CPT2 (matrix side of the inner mitochondrial membrane). Long-chain fatty acyl-CoA is converted to acylcarnitine by CPT1 (requiring carnitine), transported into the mitochondrial matrix by CACT, reconverted to acyl-CoA by CPT2, and then oxidized by the beta-oxidation enzymes.
In CPT1A deficiency, entry of long-chain FA into hepatic mitochondria is blocked. When glycogen is depleted in the fasting state, the liver must rely on fatty acid beta-oxidation, but because this pathway is unavailable due to CPT1A deficiency, ketone body production is extremely suppressed. As a result, hypoketotic hypoglycemia develops and the brain and peripheral tissues face energy deficiency. Long-chain FA that cannot be partially oxidized cause fat deposition in hepatocytes, leading to liver dysfunction such as elevated transaminases. CPT1A activity is regulated by inhibition by malonyl-CoA, the product of acetyl-CoA carboxylase, and this mechanism serves as a physiological control that suppresses fatty acid oxidation in the fed state.
In CPT2 deficiency, acylcarnitines cannot be reconverted to acyl-CoA in the mitochondrial matrix, blocking beta-oxidation. In myopathic CPT2, residual enzyme activity can meet fatty acid requirements at rest, but when the demand for long-chain FA oxidation surges due to prolonged exercise, fasting, fever and the like, insufficient ATP production and accumulation of toxic long-chain acylcarnitines cause muscle damage (rhabdomyolysis). In neonatal CPT2, almost complete enzyme deficiency severely blocks the energy supply to organs throughout the body, such as the myocardium, liver and kidneys, so fatal multisystem failure appears from the neonatal period.
Symptoms of CPT1A deficiency: The main age of onset is infancy (6–18 months of age), and typical triggers are fever from infection (especially gastroenteritis) and poor feeding. The main symptoms are decreased consciousness (lethargy to coma), hypoglycemia (low blood glucose), hepatomegaly, vomiting and hypotonia. Jaundice may appear when liver dysfunction accompanies it. Absent or very slight ketonuria is characteristic (hypoketotic hypoglycemia). If not treated properly, it can lead to acute liver failure, cerebral edema and death. In Inuit populations, it sometimes first presents as unexpected sudden death (SIDS-like) in breastfed infants.
CPT2 deficiency — myopathic form (adult form): The most common phenotype, mainly first diagnosed in adults in their 10s–30s. The typical symptoms are myalgia and muscle cramps after or during prolonged exercise. Strenuous and sustained exercise (marathons, hiking, long-distance cycling, etc.), fasting, fever, hypothermia, sleep deprivation, stress and some drugs (statins, anesthetics) trigger symptoms. When rhabdomyolysis occurs, brown urine (myoglobinuria), muscle swelling and extreme CK elevation appear, and in severe cases it progresses to acute renal failure. Patients are completely normal between attacks.
CPT2 deficiency — neonatal/infantile form: The neonatal form is the most severe, with multisystem involvement (cardiomyopathy, arrhythmia, liver failure, hypoglycemia, renal dysplasia, brain abnormalities) appearing right after birth and high early mortality. The infantile form presents a few months after birth with hypoglycemia and hepatic symptoms triggered by fever or fasting, accompanied by muscle and cardiac involvement.
Laboratory findings in myopathic CPT2: In episodes of rhabdomyolysis, serum creatine kinase (CK) rises to tens to thousands of times the upper limit of normal. Plasma acylcarnitine analysis characteristically shows elevated long-chain acylcarnitines (palmitoylcarnitine C16:0, stearoylcarnitine C18:0, oleoylcarnitine C18:1). In the acute phase, myoglobinuria produces brown urine, positive urine myoglobin and elevated serum BUN and creatinine (when renal failure accompanies it). Between episodes, all tests may normalize. Reactions resembling malignant hyperthermia may occur during anesthesia, so caution is needed before anesthesia.
Laboratory findings in CPT1A deficiency: Hypoketotic hypoglycemia is the key finding. Plasma acylcarnitine analysis characteristically shows increased free carnitine (C0), low or normal long-chain acylcarnitines (C16, C18) and a low acylcarnitine/free carnitine (A/F) ratio. This reflects the paradoxical phenomenon in which free carnitine accumulates because long-chain FA cannot be converted to acylcarnitines in CPT1A deficiency. Elevated AST and ALT, hyperammonemia and prolonged PT reflect reduced liver function. On physical examination, hepatomegaly, jaundice and decreased consciousness are observed in the acute phase. Brain MRI may show basal ganglia and white matter damage in acute hypoglycemic encephalopathy.
Newborn screening for CPT deficiency is performed by tandem mass spectrometry (MS/MS)-based acylcarnitine profile analysis. The main screening markers for CPT2 deficiency are elevated plasma palmitoylcarnitine (C16), stearoylcarnitine (C18:0) and oleoylcarnitine (C18:1). However, elevated C16 and C18 also occur in other long-chain FAO disorders such as VLCAD deficiency and LCHAD deficiency, so confirmatory testing is always necessary. For screening of CPT1A deficiency, a marked increase in free carnitine (C0) and a low acyl/free carnitine ratio (A/F < 0.1) on acylcarnitine analysis are the markers.
In Inuit and Alaska Native populations, targeted analysis of the CPT1A p.Pro479Leu variant has been used for screening, and the state of Alaska includes this test in its newborn screening program. In Korea, CPT deficiency is not currently officially included in the standard newborn screening panel, but if an abnormal pattern is found on expanded screening acylcarnitine analysis, the patient is referred to a specialist center. In at-risk groups with a family history, early diagnosis is possible with ABCD1 molecular genetic testing.
Confirmation of CPT deficiency is made by combining biochemical tests, enzyme activity measurement and molecular genetic testing. Plasma acylcarnitine analysis: CPT2 deficiency is characterized by elevated C16:0, C18:0 and C18:1 acylcarnitines. CPT1A deficiency is characterized by elevated C0 and a reduced A/F ratio. Acute-phase samples show biochemical abnormalities more clearly, and they may normalize between episodes. Urine organic acid analysis: A mild elevation of dicarboxylic acids may appear, but there are no distinctive findings. Enzyme activity measurement: CPT1A or CPT2 enzyme activity is measured in cultured skin fibroblasts. Enzyme activity below 10% of normal controls is diagnostic.
Genetic analysis: NGS-based testing of the CPT1A or CPT2 gene is the standard for molecular confirmation. In CPT2, the myopathic form is diagnosed by confirming homozygosity or compound heterozygosity for the p.Ser113Leu variant. In neonatal CPT2, complete loss-of-function variants are identified. Exercise provocation test: In myopathic CPT2, a standardized bicycle ergometer exercise protocol is used to measure CK, plasma acylcarnitines and serum lactate and ammonia before and after exercise. A marked rise in CK after exercise is characteristic of myopathic CPT2. Muscle biopsy: Pathologically, excess lipid accumulation (lipid storage) is seen, and immunofluorescence staining with CPT2 antibodies can confirm loss or reduction of CPT2 protein.
Treatment of CPT1A deficiency: Avoidance of fasting is key. In infants, regular feeding is maintained and fasting duration is limited according to age (maximum 4 hours for newborns, maximum 8 hours for infants). During infection or fever, if oral intake is impossible, intravenous glucose supplementation (10% glucose infusion, 8–10 mg/kg/min) is started immediately. The diet is basically low-fat and high-carbohydrate, and medium chain triglyceride (MCT) oil can be used as a supplementary energy source. Excessive intake of long-chain fatty acids is avoided, and energy is supplied with sufficient carbohydrate and protein. Before surgery, consultation with anesthesiology and metabolic disease specialists is arranged to plan shortened preoperative fasting and maintenance of intraoperative glucose infusion.
Treatment of myopathic CPT2: Avoidance of triggers (precipitating factors) is the most effective preventive strategy. Muscle glycogen is maintained by sufficient carbohydrate intake before prolonged exercise, and carbohydrates are replenished regularly during exercise as well. Triggers such as prolonged fasting, fever, hypothermia, excessive fatigue, statin drugs and ibuprofen are avoided. Because there is a risk of malignant hyperthermia-like reactions during anesthesia, advance notification of the anesthesiology team is essential. MCT dietary supplementation may help reduce dependence on long-chain FA. There are small reports that a trial of riboflavin (vitamin B2) 500 mg/day reduces episode frequency in some patients. In the acute phase of rhabdomyolysis, renal failure is prevented by sufficient fluid administration (isotonic saline, maintaining urine output >200 mL/h), and electrolyte abnormalities are corrected. Dialysis may be required if acute renal failure develops.
The prognosis of CPT1A deficiency is determined by early diagnosis and management to avoid fasting. Patients diagnosed at the presymptomatic stage through newborn screening or family history can achieve normal development and a normal life expectancy with appropriate feeding management and adherence to emergency protocols. Before diagnosis, or when acute hypoglycemic crises are untreated, permanent neurological damage (intellectual disability, epilepsy, movement disorders) or death may result. In Inuit populations, there have been cases in which CPT1A-related sudden death acted as a cause of SIDS, emphasizing the importance of early screening and education in these populations.
The prognosis of myopathic CPT2 is generally good. With effective trigger avoidance and lifestyle adjustment, a normal life expectancy and good quality of life are possible. The most serious acute complication is acute renal failure due to severe rhabdomyolysis. In such cases, renal function is protected by immediate fluid therapy and, if needed, dialysis. In the long term, repeated episodes of rhabdomyolysis can progress to chronic kidney disease, so monitoring of renal function is important. Neonatal CPT2 has a very poor prognosis, and death often occurs within days to weeks after diagnosis. There is currently no effective treatment for the neonatal form. Infantile CPT2 has an intermediate prognosis, and some survival is possible with avoidance of fasting and aggressive treatment in the acute phase.
For primary prevention, newborn screening (MS/MS acylcarnitine analysis) and genetic counseling are key. When a family member with CPT deficiency has been identified, molecular genetic testing is performed on at-risk family members (siblings, children) to pursue early diagnosis. In particular, screening for the CPT1A p.Pro479Leu variant is recommended in Inuit and Alaska Native populations. In carrier parents, whether the fetus is affected can be determined in advance through prenatal diagnosis (CVS, amniocentesis) or PGT.
Secondary prevention is the prevention of metabolic crises and complications in confirmed patients. Both caregivers and patients always carry an emergency protocol card and disclose the diagnosis immediately on visiting the emergency department. For surgery and anesthesia, consultation with metabolic disease specialists and anesthesiology in advance is mandatory. In myopathic CPT2, education on trigger avoidance is key. Education covers carbohydrate intake before prolonged exercise, sufficient fluid intake, and adjustment of exercise intensity and duration. In stressful situations such as fever, infection and surgery, triggers are avoided more strictly, and patients visit a medical facility immediately if symptoms occur. For tertiary prevention, periodic monitoring of renal function (myopathic CPT2) and assessment of neurocognitive development (CPT1A) are needed.